DOCSLIB.ORG

Adooq Bioscience Kinase Inhibitors Catalog 2014-2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Adooq Bioscience Innovation through Bioscience Kinase Inhibitors Catalog 2014-2015 Adooq Bioscience LLC.©2015 4000 Barranca Parkway, Suite 250 Irvine, CA 92604, USA Phone: 1-866-930-6790 www.adooq.com Fax: 1-866-333-9607 Email: [email protected] I About Us Distributors II About Us Worldwide Distributors Who We Are Australia Sapphire Bioscience Pty. Ltd. Austria Hölzel Diagnostika Handels GmbH www.sapphirebioscience.com www.hoelzel-biotech.com [email protected] [email protected] Tel: 1800 062 088 Fax: +61296981022 Tel: +49(0)221-1260266 Fax: +49(0)221-1260267 Adooq Bioscience is one of the world leading suppliers of high-performance life- Canada Cedarlane China Shenzhen Minn Bolin Bio-Tech Co., Ltd. science reagents and reference compounds for the research fields. Now, Adooq www.cedarlanelabs.com www.mbolin-lktlabs.com/cn has more than 4200 products with validated biological and pharmacological [email protected] [email protected] Tel: +1(289)288-0001 Fax: +1(289)288-0020 Tel: +86-755-2510-6053 Fax: +86-755-2510-6053 activities, and an unique collection of over 2000 inhibitors on HDAC, PI3K, China Guangzhou Whiga Technology ltd. China ADVANCED TECH. & IND. CO., LTD. Apoptosis and more signaling pathways in stock. www.whiga.com.cn www.advtechind.com [email protected] [email protected] Tel: +862084224519 Fax: +862084224925 Tel: +852-23902293 Fax: +852-27898314 Global Scope France CliniSciences Germany Hölzel Diagnostika Handels GmbH www.clinisciences.com www.hoelzel-biotech.com [email protected] [email protected] Adooq has more than 25 distributors in 30 different countries all over the Tel: +33 9 77 40 09 09 Fax: +33 9 77 40 10 11 Tel: +49(0)221-1260266 Fax: +49(0)221-1260267 world. Our worldwide marketing network supports first-class service on five Hungary Bio-Science Ltd. India Biogenuix Medsystems Pvt Ltd www.bio-science.hu www.biogenuix.com continents. [email protected] [email protected] Tel: (06-1) 463-5077 Fax: (06-1) 463-5261 Tel: 91-11-25612008 Fax: 91-11-45513884 Indonesia PT Sciencewerke. Ireland Bioquote Limited Technology and Quality www.sciencewerke.com www.bioquote.com [email protected] [email protected] Tel: +62 21 7203678 Fax: +62 21 7398723 Tel: 00 44 1904 431402 Fax: 00 44 1904 431409 Adooq focuses on technologies that improve our ability to find, develop and Israel ENCO Scientific Services Italy CliniSciences www.enco.co.il www.clinisciences.com produce life-science reagents. The safety and effectiveness of all Adooq products [email protected] [email protected] has been demonstrated through preclinical and clinical research. Tel: 972-3-934-9922 Fax: 972-3-934-9876 Tel: +39 06 94 80 56 71 Fax: +39 06 94 80 00 21 Japan FUNAKOSHI CO., LTD. Lebanon DPC/LEBANON SARL www.funakoshi.co.jp www.dpcleb.com [email protected] [email protected] Quick Delivery Tel: +81-3-5684-1653 Fax: +81-3-5684-1654 Tel: +961-1511545 Fax: +961-1502812 Malaysia Sciencewerke Sdn Bhd Morocco HexaBiogen www.sciencewerke.com www.hexabiogen.com For U.S. based customers, Adooq guarantees that orders placed by 3:30 p.m. (U.S. [email protected] [email protected] Pacific Time) will arrive the next day before 10:30 a.m (U.S. local time). Adooq Tel: +60 3 7846 4244 Fax: +60 3 7847 4244 Tel: +212 5 39 93 35 05 Fax: +212 5 39 93 75 59 has an established marketing network outside of U. S.. No matter where you are New Zealand Sapphire Bioscience (NZ) Ltd. Singapore Sciencewerke Pte Ltd . www.sapphirebioscience.com www.sciencewerke.com located across the globe, if your purchased items are in stock, Adooq will initiate [email protected] [email protected] the shipping process within 24 hours. Tel: 1800 062 088 Fax: +61296981022 Tel: +65 6777 1045 Fax: +65 6777 3054 South Korea Bioclone Corp. South Korea LeehyoBioscience Co., Ltd www.bioclone.co.kr www.leehyobio.com Our Mission [email protected] [email protected] Tel: +82-2-2690-0058 Fax: +82-2-2690-0397 Tel: +82-31-722-2382 Fax: +82-31-759-7641~3 Spain CliniSciences Switzerland Hölzel Diagnostika Handels GmbH Adooq recognizes that the world needs the life-science reagents, especially www.clinisciences.com www.hoelzel-biotech.com [email protected] [email protected] some inhabitiors for the cancer research, in every potential form. That’s why Tel: +34 512 702 901 Fax: +34 512 702 902 Tel: +49(0)221-1260266 Fax: +49(0)221-1260267 Adooq’s employees work to responsibly develop the affordable, reliable life- Taiwan ASIA BIOSCIENCE CO.,LTD. United Kingdom Bioquote Limited science reagents the world needs. You are welcomed to join or work with us www.abscience.com.tw www.bioquote.com [email protected] [email protected] creating innovations that matter to people! Tel: +886-2-2827-1197 Fax: +886-2-2827-7780 Tel: 00 44 1904 431402 Fax: 00 44 1904 431409 Adooq Bioscience LLC. © 2015 Email: [email protected] Phone: 1-866-930-6790 Fax: 1-866-333-9607 III Contents Contents IV Cathepsin 34 Progesterone Receptors 44 Histone demethylases 34 Renin-angiotensin-aldosterone system (RAAS) 45 Stem Cell Differentiation 34 Androgen Receptors 45 Contents PPAR 45 GSK-3 / Wnt / Hedgehog ..............................35 Liver X receptors (LXRs) 45 Aromatase 46 Apoptosis .................................................................1 PI3K / Akt / mTOR........................................20 γ-Secretase 35 Retinoic Acid Receptors 46 Bcl-2 Family 1 Akt 20 Hedgehog 35 Glucocorticoid receptors 46 Caspase 1 Ferroptosis 20 Wnt 35 p53 1 PI3-Kinase (PI3K) 20 β-catenin 36 GSK-3 36 Transferases ..........................................................46 TNF-α 1 mTOR 22 IAP 1 PDK1 23 Smoothened 36 Glucocorticoid receptors 46 RasGAP (Ras- P21) 2 Vitamin D Receptors 46 PERK 2 Transporters .........................................................37 GnRH receptor 46 Receptor Tyrosine Kinases .................................23 GPR 46 EGFR/HER2 23 ATPase 37 Phosphorylases 46 Angiogenesis ............................................................2 DNA-dependent protein kinase (DNA-PK) 23 Multidrug Transporters 37 Methyltransferases 47 EGFR / HER2 2 Ribosomal S6 protein kinases (RSK) 23 Sodium-dependent Glucose Cotransporter (SGLT) 37 Protein Prenyltransferases 47 MDM2 2 FGFR 24 Monocarboxylate transporters (MCT) 37 FPTase 47 Apoptosis Inducers 2 PDGFR 24 Neurotransmitter Transporters 38 Histone Methyltransferase 47 FGFR 3 VEGFR 24 AMPA receptor 38 Histone Acetyltransferases 47 PDGFR 3 Type 1 insulin-like growth factor receptor (IGF-1R) 24 DNA Methyltransferases 47 VEGFR 3 FLT3 (FMS-like tyrosine kinase 3) 25 Ion Channels ........................................................38 Vascular Disrupting Agent (VDA) 4 c-MET 25 Calcium Channels 38 Ubiquitin ..............................................................48 HIF 5 ALK 25 P-gp 38 BCR-ABL 26 activating enzyme E1 48 CRM1 38 E3 ubiquitin ligase 48 MAPK ......................................................................5 FAK 26 Ligand-gated Ion Channels 38 SRC 26 DUB 48 MEK/ERK 5 Sodium Channels 39 c-Kit 27 5-alpha-reductase 5 Potassium Channels 39 Spleen tyrosine kinase (Syk) 27 Others ....................................................................48 Antiangiogenics 5 Chloride Channels 39 Tie-2 27 p38-MAPK 6 Cystic Fibrosis Transmembrane Regulator (CFTR) 39 Other inhibitors 48 Bone Morphogenetic Proteins (BMP) 28 JNK/c-Jun 6 Transient Receptor Potential Channels 40 p97 48 Bruton's tyrosine kinase 28 Raf 6 Carbonic Anhydrase 54 AMPK / Insulin Receptor ...............................40 Cholinesterase 54 NF-kB/IkB ..........................................................28 Casein Kinase 2 54 Cell Cycle .................................................................7 AMPK 40 NF-kB 28 Soluble guanylyl cyclase (sGC) 54 Checkpoint Kinase 7 Axl 28 Reagents 54 cyclin-dependent kinases (CDKs) 8 ATM / ATR ........................................................40 Tyrosine kinase 28 Integrin Receptors 54 Checkpoint Control Kinases 9 Trk Receptors 28 ATM 40 Toll-like Receptors 54 Aurora Kinase 9 Cytokines 29 NMDA Receptors 40 Beta-secretase (BACE) 54 PARP 9 IKK 29 ATR 40 LRRK2 54 Polo-like kinases (PLKs) 10 MELK 54 Rho-Kinase (ROCKs) 10 7-TM Receptors .................................................41 β-lactamase 55 Topoisomerase 11 JAK / Stat ............................................................29 Gluconeogenesis 55 Microtubules 11 JAK 29 5-HT Receptors 41 Cholinesterases 55 Synthases / Synthetases 12 Stat 29 Adrenergic Receptors 41 Aldose Reductase 55 RNA/DNA Polymerase 12 Pim Kinase 29 Acetylcholine Muscarinic Receptors 42 Nitric Oxide Signaling 55 Telomerase 12 Histamine Receptors 42 Adenylyl Cyclase 55 Ligases 12 TGF-β / Smad ...................................................30 Dopamine Receptors 42 IDH1 55 Reverse Transcriptase 12 Opioid Receptors 42 LSD1 inhibitor 55 TGF-β/ Smad Inhibitors 30 GABA Receptors 42 Protein Kinase C (PKC) 30 Casein Kinase 1 55 Cell Metabolism ..................................................13 Purinergic (P2Y) Receptors 42 Lipoxygenase 55 Metabotropic glutamate receptors (mGluR) 43 Sigma-1 receptor 55 Cytochrome P450 13 Proteases ................................................................30 Angiotensin Receptors 43 Mitosis 13 Caspase 30 Melatonin Receptors 43 -Amyloid 14 β Protein Kinase A 30 Peptide Receptors 43 Phosphodiesterases (PDEs) 14 Protein kinase D (PKD) 30 Smoothened Receptors 43 Hydroxylases 14 Proteasome 30 Chemokine Receptors (CCR5) 43 Dihydrofolate reductase (DHFR) 15 HCV Protease 31 G Protein 43 Dehydrogenases 15 HIV Protease
Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor

    Endothelin System and Therapeutic Application of Endothelin Receptor

    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
  • Neuroscience Product Handbook

    Neuroscience Product Handbook

    www.MedChemExpress.com MedChemExpressMedChemExpress Neuroscience Product Handbook Pain Biological Rhythms and Sleep Neuromuscular Diseases AutonomicNeuroendocrine Somatosensation metabolism Regulation Processes transduction Behavioral Neuroethology Neuroendocrin feature soding Food Intake oral and speech From the itineraries of and Energy Balance vocal/social 8,329 attendees Touch Thirst and communication Water Balance social behavior Development peptides at the 2018 SfN meeting Ion Channels and Evolution Stress and social cognition opiates the Brain monoamines Spinal Cord Adolescent Development PTSD Injury and Plasticity Postnatal autism Developmental fear Neurogenesis Disorders human social Mood cognition ADHD, Disorders Human dystexia Anxiety Cognition and Neurogenesis depression Appetitive Behavior and Gllogenesis bipolar and Aversive timing Development of Motor, Schizophrenia Learning perception Sensory,and Limbic Systems perceptual learning Other Psychiatric executive attention Stem Cells... mitochondria Emotionfunction human Parkinson's Glial Mechanisms biomarkers reinforcement long-term Disease Synaptogenesis human human memory Huntington's Transplant and ... Development Neurotransm., Motivation decisions working and Regen Axon and Transportors, memory PNS G-Protein...Signaling animal Dendrite reward decision visual Other Movement Development Receptors learning and memory model microglia making decisions Disorders Demyelinating NMDA dopamine ataxia Disorders place cells, GABA, LT P Synaptic grid cells gly... Plasticity striatum
  • FY 2020 Results Conference Call and Webcast for Investors and Analysts

    FY 2020 Results Conference Call and Webcast for Investors and Analysts

    FY 2020 results Conference call and webcast for investors and analysts 11 February 2021 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure
  • Zibotentan, an Endothelin a Receptor Antagonist, Prevents Amyloid-Я

    Zibotentan, an Endothelin a Receptor Antagonist, Prevents Amyloid-Я

    Journal of Alzheimer’s Disease 73 (2020) 1185–1199 1185 DOI 10.3233/JAD-190630 IOS Press Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid-␤-Induced Hypertension and Maintains Cerebral Perfusion Jennifer C. Palmera,1, Hannah M. Taylera,1, Laurence Dyera, Patrick G. Kehoea, Julian F.R. Patonb and Seth Lovea,∗ aTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK bDepartment of Physiology, Faculty of Medical & Health Sciences, University of Auckland, New Zealand Accepted 25 November 2019 Abstract. Cerebral blood flow is reduced in Alzheimer’s disease (AD), which is associated with mid-life hypertension. In people with increased cerebral vascular resistance due to vertebral artery or posterior communicating artery hypoplasia, there is evidence that hypertension develops as a protective mechanism to maintain cerebral perfusion. In AD, amyloid-␤ (A␤) accumulation may similarly raise cerebral vascular resistance by upregulation of the cerebral endothelin system. The level of endothelin-1 in brain tissue correlates positively with A␤ load and negatively with markers of cerebral hypoperfusion such as increased vascular endothelial growth factor. We previously showed that cerebroventricular infusion of A␤40 exacerbated pre- existing hypertension in Dahl rats. We have investigated the effects of 28-day cerebral infusion of A␤40 on blood pressure and heart rate and their variability; carotid flow; endothelin-1; and markers of cerebral oxygenation, in the (normotensive) Wistar rat, and the modulatory influence of the endothelin A receptor antagonist Zibotentan (ZD4054). Cerebral infusion of A␤ caused progressive rise in blood pressure (p < 0.0001) (paired t-test: increase of 3 (0.1–5.6) mmHg (p = 0.040)), with evidence of reduced baroreflex responsiveness, and accumulation of A␤ and elevated endothelin-1 in the vicinity of the infusion.
  • Experimental Models of Prostate Cancer Bone Metastasis - Establishment, Characterization and Imaging of Xenograft Bone Metastasis Models

    Experimental Models of Prostate Cancer Bone Metastasis - Establishment, Characterization and Imaging of Xenograft Bone Metastasis Models

    Experimental Models of Prostate Cancer Bone Metastasis - Establishment, characterization and imaging of xenograft bone metastasis models - PhD thesis presented by Marta Garcia López To obtain the degree of PhD for the Universitat Autònoma de Barcelona (UAB) PhD thesis done at the Research Unit in Biomedicine and Translational and Pediatrics Oncology, at the Vall d’Hebron Research Institute, Vall d’Hebron Hospital, under the supervision of Drs. Jaume Reventós i Puigjaner, Andreas Doll and Juan Morote Robles Doctoral study in Biochemistry, Molecular Biology and Biomedicine. Universitat Autònoma de Barcelona, Faculty of Bioscience, Department of Biochemistry and Molecular Biology Universitat Autònoma de Barcelona, 2013 Dr. Jaume Reventós Puigjaner Dr. Andreas Doll Dr. Juan Morote Robles Marta Garcia López No entiendes realmente algo a menos que seas capaz de explicárselo a tu abuela. Albert Einstein Summary In industrialized countries, prostate cancer (PCa) is the most common malignancy in men, but mortality rates are much lower than those recorded in developing countries, reflecting benefits from advances in early diagnosis and effective treatment. However, the metastatic disease rather than the primary tumour is responsible for much of the resulting morbidity and mortality. Skeletal metastases occur in more than 70% of cases of late-stage of PCa and they confer a high level of morbidity, a 5-year survival rate of 25% and median survival of approximately 40 months. Though fractures and spinal cord compression are potential complications, the most common symptom of bone metastases is pain. Bone metastases from PCa lead to an accelerated bone turnover state that features pathological activation of both osteoblasts and osteoclasts.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project

    HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project

    University of Rhode Island DigitalCommons@URI Infectious Diseases in Corrections Report (IDCR) 2003 HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project Follow this and additional works at: http://digitalcommons.uri.edu/idcr Recommended Citation HIV & Hepatitis Education Prison Project, "HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6" (2003). Infectious Diseases in Corrections Report (IDCR). Paper 46. http://digitalcommons.uri.edu/idcr/46 This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. HIV & HEPATITIS EDUCATION PRISON HEPJune 2003 Vol. 6, Issue 6 P REPORT PROJECT Infectious Diseases in Corrections SPONSOREDBYTHEBROWNMEDICALSCHOOLOFFICEOFCONTINUINGMEDICALEDUCATION. ABOUT HEPP Long-Term Toxicities Associated with HIV and HEPP Report, a forum for Antiretroviral Therapy correctional problem solving, targets correctional physicians, nurses, By Peter J. Piliero, M.D.*, Associate Professor of Medicine, Albany Medical College administrators, outreach workers, and Soon after the introduction of the first antiretroviraldine (3TC) have also been associated with pan- case managers. Published monthly (ARV) agent, zidovudine (AZT), drug-related toxi-creatitis. There may be an added potential for pan- and distributed by email and fax, cities became recognized and well-characterized.creatitis when using combinations of these nucle- HEPP Report provides up-to-the Things have since become more complicated;oside reverse transcriptase inhibitors (NRTIs). moment information HIV/AIDS, there are now 17 ARV agents in four distinct class-Importantly, the concomitant use of alcohol hepatitis, and other infectious es.
  • Endocrine Abstracts Vol 65

    Endocrine Abstracts Vol 65

    Endocrine Abstracts November 2019 Volume 65 ISSN 1479-6848 (online) Society for Endocrinology BES 2019 11–13 November 2019, Brighton published by Online version available at bioscientifica www.endocrine-abstracts.org Volume 65 Endocrine Abstracts November 2019 Society for Endocrinology BES 2019 11–13 November 2019, Brighton VOLUME EDITORS The abstracts submitted were marked by the Abstract Marking panel, selected by the Programme Organising Committee. Programme Committee D Bassett (Programme Secretary) (London) Laura Matthews (Leeds) Andrew Childs (Programme Co-ordinator) (London) Carla Moran (Cambridge) Nils Krone (Programme Co-ordinator) (Sheffield) Annice Mukherjee (Salford) Helen Simpson (Programme Co-ordinator) (London) Francesca Spiga (Bristol) Davide Calebiro (Birmingham) Jeremy Tomlinson (Oxford) Ben Challis (Cambridge) Jennifer Walsh (Sheffield) Mandy Drake (Edinburgh) Abstract Marking Panel Ramzi Ajjan (Leeds) Neil Gittoes (Birmingham) John Newell-Price (Sheffield) Richard Anderson (Edinburgh) Helena Gleeson (Birmingham) Mark Nixon (Edinburgh) Ruth Andrew (Edinburgh) Philippa Hanson (London) Finbarr O’Harte (Ulster) Weibke Arlt (Birmingham) Martin Hewison (Birmingham) Adrian Park (Cambridge) Mo Aye (Hull) Claire Higham (Manchester) Simon Pearce (Newcastle) Tom Barber (Warwick) Steve Hillier (Edinburgh) Andrew Powlson (Cambridge) Duncan Bassett (London) Andy James (Newcastle) Teresa Rea (Belfast) Roger Brown (Edinburgh) Channa Jayasena (London) Martin Read (Birmingham) Paul Carroll (London) Niki Karavitaki (Oxford) Aled Rees (Cardiff)
  • G Protein-Coupled Receptors

    G Protein-Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
  • G Protein‐Coupled Receptors

    G Protein‐Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
  • Fatal Fungemia with Scedosporium Prolificans in a Patient with Acute Myeloid Leukemia

    Fatal Fungemia with Scedosporium Prolificans in a Patient with Acute Myeloid Leukemia

    Med. Mycol. J. Med. Mycol. J. Vol. 55（No. 4）, 2014 E 63 Vol. 55E, E 63 − E 70, 2014 ISSN 2185 − 6486 Case Report Fatal Fungemia with Scedosporium prolificans in a Patient with Acute Myeloid Leukemia Makoto Nishimoriઃ, Toshio Takahashi઄, Eiko Suzuki઄, Taiichi Kodakaઃ, Nobuhiro Hiramotoઃ, Kiminari Itohઃ, Hiroko Tsunemineઃ, Kyoko Yaritaઅ, Katsuhiko Kameiઅ, Hiroshi Takegawaઆ, Takayuki Takahashiઃ ઃDepartments of Hematology Shinko Hospital, Kobe ઄Laboratory Medicine, Shinko Hospital, Kobe અMedical Mycology Research Center, Chiba University, Chiba આLaboratory Medicine, Kobe City Medical Center General Hospital, Kobe ABSTRACT Scedosporium prolificans（S. prolificans）is a type of mold, which rarely affects immunocompromised people. We treated a 71-year-old woman with acute myeloid leukemia（AML-M5a）with low-dose cytarabine, acralubicin, and filgrastim as the induction therapy. On day 7 after the initiation of chemotherapy, she became febrile and agranulocytic, and developed anal pain; therefore, we discontinued the chemotherapy on day 8. Broad-spectrum antibiotics, micafungin, and then liposomal amphotericin B were ineffective. The serum concentration of β-D-glucan was 525 pg/mL. She died of multiple organ failure on day 17. S. prolificans was detected from the blood culture on day 13. Physicians should consider Scedosporium spp. infection when principal antifungal agents are ineffective and fungal infection is strongly suspected. Key words：Scedosporium prolificans, acute myeloid leukemia, β-D-glucan, mold sinuses, or through direct inoculation, such as in Introduction skin puncture 4）. S. prolificans-affected body regions include the blood, lungs, bones, and soft Scedosporium species（spp.）are ubiquitous tissue, and S. prolificans disseminates to multiple fungi, distributed in living environments such as organs in many cases.
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By

    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.